title: Restrictions on interactions between doctors and industry could ultimately hurt patients.
abstract: Physician-industry collaboration has led to a diverse array of therapeutic advancements that have benefitted a broad spectrum of patient populations. Evolving regulations, both institutional and governmental, aiming to govern interactions between physicians and pharmaceutical and medical device manufacturers have become increasingly prevalent. Emerging data suggest that restrictions on physician-industry collaboration have the potential to harm patient care by degrading innovation and stifling medical education. The following article reviews the effects of legislation on medical innovation as well as the impact on continuing medical education.
authors.affiliation: Cardiac Catheterization Laboratory and Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA. ckimmelstiel@tuftsmedicalcenter.org
authors.forename: Carey
authors.initials: C
authors.lastname: Kimmelstiel
mesh_terms: D032781:Codes of Ethics; D016265:Conflict of Interest / Q000331:legislation & jurisprudence; D003299:Cooperative Behavior; D004059:Diffusion of Innovation; D004502:Education, Medical, Continuing / Q000331:legislation & jurisprudence; D033161:Government Regulation; D017408:Guidelines as Topic; D019981:Health Care Sector / Q000941:ethics / Q000331:legislation & jurisprudence* / Q000592:standards; D006291:Health Policy; D006801:Humans; D007373:Interinstitutional Relations; D007400:Interprofessional Relations / Q000941:ethics; D010818:Practice Patterns, Physicians' / Q000331:legislation & jurisprudence; D011787:Quality of Health Care / Q000941:ethics / Q000331:legislation & jurisprudence* / Q000592:standards; D015871:Scientific Misconduct